- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Contrast unavailability in U.S. harms diagnostic ultrasound
"We have so many CT and MR machines in the U.S. providing quick, easy, and efficient imaging that it's hard for ultrasound to compete, especially when it comes down to physicians' time.
"We have so many CT and MR machines in the U.S. providing quick, easy, and efficient imaging that it's hard for ultrasound to compete, especially when it comes down to physicians' time.
"I don't think any radiologist would be happy to give a final diagnosis on metastatic disease in the liver using CT or MRI without a contrast agent. We do not have the advantage of using contrast agents with ultrasound in this country, since they have not been approved by the FDA.
"Having contrast agents readily available will help improve ultrasound's diagnostic capabilities in many ways, including bedside imaging of patients who cannot be transported. One of the AIUM's new initiatives is to work with the FDA to accelerate the approval process."
-Lennard Greenbaum, M.D., president of the American Institute of Ultrasound in Medicine, speaking at the AIUM meeting in June
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
